Drugs / Diethylcarbamzine
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT07159373 Background | Sep 2026 → Jun 2027 expected | filariasis, scabies, strongyloidiasis | Medicines Development for Global Health | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Diethylcarbamzine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07159373 ↗ |
| Known as | DEC | “MoxDA - Moxidectin + Diethylcarbamzine (DEC) + Albendazole” NCT07159373 ↗ |